This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Pathogenesis

Authoring team

Only susceptible individuals develop emphysema but in most cases the factors governing susceptibility are poorly understood.

The alveolar wall destruction typical of emphysema may be explained by the protease-antiprotease theory. The pulmonary protease is elastase derived from neutrophils and macrophages; the principal anti-protease is alpha-1 antitrypsin.

The main elements of the theory are:

  • tobacco smoke and other irritants result in inflammation and the influx of neutrophils and macrophages into the alveoli and bronchioles
  • elastase is released which breaks down elastin fibres and other structural proteins
  • serine protein inhibitors, principally alpha-1 antitrypsin, down-regulate the tissue destruction
  • chronic inflammation eventually degrades alveolar walls
  • protease overactivity is favoured by:
    • inactivation of alpha-1 antitrypsin by oxidants in smoke and oxygen free radicals secreted by neutrophils
    • hereditary deficiency in alpha-1 antitrypsin activity

Heavy smoking alone causes emphysema around the 6th decade.

Homozygotes for alpha-1 AT deficiency develop severe emphysema around the 4th decade. This is accelerated in smokers.

Weight loss, which is a common feature of the illness, and which is associated with increased morbidity and mortality, is thought to result from the release of TNF-alpha from hypoxic tissues.


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.